For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

SALT LAKE CITY, UTAH / ACCESS Newswire / February 6, 2025 /CenExel, a leading network of clinical research sites, proudly ...

For the first time in decades, a new class of painkiller has been approved by the US Food and Drug Administration (FDA).

The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...

Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.

Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex ...

Clinical trials for JOURNAVX were conducted at four CenExel Centers of Excellence in Salt Lake City, UT; Tampa, FL; Anaheim, CA; and Atlanta, GA. These sites provided critical data that ...

Vertex Pharmaceuticals (NASDAQ:VRTX) received an upgrade from Canaccord Genuity after the cystic fibrosis drugmaker exceeded consensus revenue estimates but missed on earnings with its Q4 2024 ...

The FDA has approved Journavx, a new non-opioid painkiller designed to treat moderate to severe acute pain. Unlike opioids, ...